Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Fourth quarter total revenues of $18.5 million; full year total revenues of $108.6 million - Rigel will receive an upfront cash payment of $125 million from Lilly for the strategic collaboration to develop Rigel's RIP1 inhibitor program - Launched a Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients - Top line data from NIH/NHLBI-sponsored Phase 2 trial of fostamatinib in COVID-19 patients expected in April 2021 - Conference call and webcast today at 4:30PM Eastern Time News ...
Source: prnewswire.com